Baillie Gifford & Co. Sells 415,493 Shares of Doximity, Inc. (NASDAQ:DOCS)

Baillie Gifford & Co. decreased its holdings in shares of Doximity, Inc. (NASDAQ:DOCS) by 7.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,943,742 shares of the company’s stock after selling 415,493 shares during the period. Baillie Gifford & Co.’s holdings in Doximity were worth $263,946,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Shaker Investments LLC OH bought a new stake in shares of Doximity during the 4th quarter valued at $559,000. Fountainhead AM LLC bought a new stake in shares of Doximity during the 3rd quarter valued at $710,000. Penserra Capital Management LLC bought a new stake in shares of Doximity during the 3rd quarter valued at $2,384,000. Newbridge Financial Services Group Inc. purchased a new position in shares of Doximity during the 4th quarter valued at $362,000. Finally, Los Angeles Capital Management LLC lifted its stake in shares of Doximity by 6,242.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 650,874 shares of the company’s stock valued at $28,359,000 after buying an additional 640,612 shares in the last quarter. Institutional investors own 87.19% of the company’s stock.

Analysts Set New Price Targets

DOCS has been the topic of a number of analyst reports. Barclays lifted their target price on shares of Doximity from $52.00 to $75.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Canaccord Genuity Group cut shares of Doximity from a “buy” rating to a “hold” rating and lifted their target price for the company from $40.00 to $60.00 in a research note on Wednesday, November 13th. KeyCorp lowered their target price on shares of Doximity from $70.00 to $65.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Leerink Partnrs upgraded shares of Doximity from a “hold” rating to a “strong-buy” rating in a research note on Friday, February 7th. Finally, Morgan Stanley upgraded shares of Doximity from an “underweight” rating to an “equal weight” rating and lifted their target price for the company from $33.00 to $53.00 in a research note on Thursday, November 14th. Eleven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Doximity presently has a consensus rating of “Moderate Buy” and a consensus target price of $64.22.

Insider Activity at Doximity

In related news, Director Timothy S. Cabral sold 20,000 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the transaction, the director now directly owns 6,360 shares in the company, valued at approximately $366,463.20. This represents a 75.87 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 37.40% of the stock is currently owned by insiders.

Doximity Stock Up 0.2 %

Doximity stock opened at $77.13 on Monday. The company’s 50-day moving average price is $57.89 and its 200-day moving average price is $47.64. Doximity, Inc. has a twelve month low of $22.96 and a twelve month high of $85.21. The company has a market cap of $14.40 billion, a PE ratio of 77.13, a price-to-earnings-growth ratio of 4.61 and a beta of 1.39.

Doximity Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.